Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | LPL | P06858 | 8/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125032 | 0.85 | LPL (0.51) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL23018698 | 0.79 | LPL (0.45) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL23018805 | 0.76 | LIPG (0.59) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL28549946 | 0.75 | LIPG (0.69) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL5899680 | 0.75 | LPL (0.51) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL18573202 | 0.75 | DGAT1 (0.53) | LPLLIPGDGAT1KDRCA1 | |
| SCHEMBL17548469 | 0.75 | LIPG (0.51) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL466348 | 0.74 | NUDT1 (0.37) | HSP90AA1AURKAPRKACAADORA2ALPL | |
| SCHEMBL1827472 | 0.74 | LIPG (0.62) | LPLLIPGKDM4EDGAT1CA1 | |
| SCHEMBL29413172 | 0.74 | LIPG (0.62) | LPLLIPGKDM4EDGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480556-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036128-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, RTF2, HCCS | HSP90AA1 1830/4885AURKA 3473/4885PRKACA 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.